Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Song, A., Li, J. Y., Cockey, S. G., Shao, R., & Zhang, H. (2024). EBV‐Positive Pleomorphic Variant Transformation of CD5‐Negative Mantle Cell Lymphoma: A Rare Case Report and Literature Review. Case Reports in Hematology, 2024(1). Portico. https://doi.org/10.1155/2024/3267739

O’Neil, D. S., Martei, Y. M., Crew, K. D., Castillo, B. S., Costa, P., Lim, T., Michel, A., Rubin, E., Goel, N., Hurley, J., Lopes, G., & Antoni, M. H. (2023). Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open, 6(12), e2346223. https://doi.org/10.1001/jamanetworkopen.2023.46223

Orlando, E. H., Gould, P., Cuzzo, B., Ford, M., Chen, Y., Sanjurjo, A., May, B., Tsapepas, D., Leeman-Neill, R. J., Bhagat, G., Dube, G., Morris, H., Arcasoy, S., Latif, F., Martinez, M., Pereira, M., Lipsky, A. H., Sawas, A., Reshef, R., … Amengual, J. E. (2023). The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder. Blood, 142(Supplement 1), 990–990. https://doi.org/10.1182/blood-2023-177823

Khatiwada, P., Soni, M., & Muranski, P. (2023). Highly Active Cytotoxic CD4 + T Cells Targeting EBV Oncoproteins with Enhanced In Vivo Anti-Tumor and Self-Renewal Properties. Blood, 142(Supplement 1), 3464–3464. https://doi.org/10.1182/blood-2023-190690

O’Neil, D. S., Ayeni, O. A., Farrow, H. A., Chen, W. C., Demetriou, G., Buccimazza, I., Čačala, S., Stopforth, L. W., Joffe, M., Antoni, M. H., Lopes, G., Pumpalova, Y. S., Mapanga, W., Jacobson, J. S., Crew, K. D., Neugut, A. I., Ruff, P., & Cubasch, H. (2023). The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer. The Oncologist, 28(10), e921–e929. https://doi.org/10.1093/oncolo/oyad056

Castellino, S. M., Giulino‐Roth, L., Harker‐Murray, P., Kahn, J. M., Forlenza, C., Cho, S., Hoppe, B., Parsons, S. K., & Kelly, K. M. (2023). Children’s Oncology Group’s 2023 blueprint for research: Hodgkin lymphoma. Pediatric Blood & Cancer, 70(S6). Portico. https://doi.org/10.1002/pbc.30580

Cherng, H.-J., Capaccione, K., Ma, H., Jambawalikar, S., Orlando, E., Ford, M., Gould, P., Cuzzo, B., Lipsky, A., Pro, B., & Amengual, J. (2023). ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder. Clinical Lymphoma Myeloma and Leukemia, 23, S442. https://doi.org/10.1016/s2152-2650(23)01337-x

Cherng, H.-J., Capaccione, K., Ma, H., Jambawalikar, S., Orlando, E., Ford, M., Gould, P., Cuzzo, B., Lipsky, A., Pro, B., & Amengual, J. (2023). POSTER: ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00722-x

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174

Geis, F. K., Kelenis, D. P., & Goff, S. P. (2022). Two lymphoid cell lines potently silence unintegrated HIV-1 DNAs. Retrovirology, 19(1). https://doi.org/10.1186/s12977-022-00602-7

de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, S. A., Rosenquist, R., Rossi, D., Salaverria, I., Steidl, C., Treon, S. P., Zelenetz, A. D., … Scott, D. W. (2022). Genomic profiling for clinical decision making in lymphoid neoplasms. Blood, 140(21), 2193–2227. https://doi.org/10.1182/blood.2022015854

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Schroers-Martin, J., Garofalo, A., Soo, J., Boegeholz, J., Alig, S. K., Sworder, B., Liu, C. L., Luikart, H., Gamino, G., Morales, D., Freystätter, K., Hamilton, J., Kurtz, D. M., Hollander, S., Rosenthal, D., Dhillon, G., Raikhelkar, J., Verleden, S., Nijland, M., … Alizadeh, A. A. (2022). Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders. Blood, 140(Supplement 1), 172–174. https://doi.org/10.1182/blood-2022-158647

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3794–3795. https://doi.org/10.1182/blood-2022-163813

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C. V., Leventhal, J. R., Friedewald, J., Ho, B., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 6674–6675. https://doi.org/10.1182/blood-2022-164724

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C., Leventhal, J. R., Ho, B., Friedewald, J., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD. Blood, 140(Supplement 1), 3833–3834. https://doi.org/10.1182/blood-2022-167812

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3777–3778. https://doi.org/10.1182/blood-2022-160147

Mahadeo, K. M., Baiocchi, R. A., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Nikiforow, S., Reshef, R., Ye, W., & Prockop, S. (2022). New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 140(Supplement 1), 10374–10376. https://doi.org/10.1182/blood-2022-157766

Orlando, E., Ford, M., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation. Blood, 140(Supplement 1), 12085–12086. https://doi.org/10.1182/blood-2022-158050

Savage, K. J., Horwitz, S. M., Advani, R., Christensen, J. H., Domingo-Domenech, E., Rossi, G., Morschhauser, F., Alpdogan, O., Suh, C., Tobinai, K., Shustov, A., Trneny, M., Yuen, S., Zinzani, P. L., Trümper, L., Ilidge, T., O’Connor, O. A., Pro, B., Miao, H., … Iyer, S. (2022). Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Advances, 6(19), 5550–5555. https://doi.org/10.1182/bloodadvances.2020003971

Ryu, Y. K., Ricker, E. C., Soderquist, C. R., Francescone, M. A., Lipsky, A. H., & Amengual, J. E. (2022). Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine, 11(16), 4928. https://doi.org/10.3390/jcm11164928

Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., … Cheah, C. Y. (2022). P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 991–992. https://doi.org/10.1097/01.hs9.0000847272.47630.ff

Prockop, S., Beitinjaneh, A., Choquet, S., Dahiya, S., Dinavahi, R., Farah, R., Gamelin, L., Ghobadi, A., Mehta, A., Nayak, P., Reshef, R., Satyanarayana, G., Stiff, P., Ye, W., & Mahadeo, K. M. (2022). S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE). HemaSphere, 6, 157–158. https://doi.org/10.1097/01.hs9.0000843916.04522.0a

Soderquist, C. R., & Bhagat, G. (2022). Indolent T- and NK-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract: Current Understanding and Outstanding Questions. Hemato, 3(1), 219–231. https://doi.org/10.3390/hemato3010018

Shou, A., Thomas, A., Kwon, W., & Kluger, M. (2022). Pancreatic Cancer After Solid-Organ Transplantation: A Descriptive Series. HPB, 24, S394. https://doi.org/10.1016/j.hpb.2022.05.836